A complainant shared four third-party posts on X (formerly Twitter) and two online articles with the PMCPA to make the case ...

Key Takeaways Moderna received a $590 million award from the U.S. government to speed development of a vaccine that could be used to fight bird flu.The biotech firm's mRNA-1018 candidate posted ...

Shares of vaccine maker Moderna fell Wednesday as Goldman Sachs lowered its rating after the biotech’s second cut to product ...

Delving into the details, we found 51% of traders were bullish, while 25% showed bearish tendencies. Out of all the trades we ...

Before beginning the discussion of where this company is going, let's set expectations appropriately. Moderna won't be revisiting its all-time highs for revenue or earnings in the next three years.

Young biotech Dropshot Therapeutics has hooked in ... Ph.D., a renowned scientist and co-founder of mRNA specialist Moderna, as well as Marijn Dekkers, Ph.D., former CEO of Bayer and Thermo ...

Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $20 ...

Moderna (MRNA) stock falls as Goldman Sachs downgrades the COVID-19 vaccine maker to Neutral from Buy, citing a lack of ...

US mRNA specialist Moderna demonstrated substantial R&D investment and progress in the UK, two years since signing its ...

Moderna received a $590 million award from the U.S. government to speed development of a vaccine that could be used to fight bird flu. The biotech firm's mRNA-1018 candidate posted positive ...